{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:27Z","timestamp":1788516447049,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101635"],"award-info":[{"award-number":["JP21nf0101635"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.11.053","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T17:11:29Z","timestamp":1701537089000},"page":"4-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune thrombocytopenic purpura and Guillain-Barr\u00e9 syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study"],"prefix":"10.1016","volume":"42","author":[{"given":"Shuntaro","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.11.053_b0005","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"de Figueiredo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.11.053_b0010","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1016\/j.vaccine.2020.09.028","article-title":"Comparison of immunization systems in Japan and the United States - What can be learned?","volume":"38","author":"Katsuta","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.053_b0015","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1016\/j.vaccine.2022.08.069","article-title":"Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study","volume":"40","author":"Ishiguro","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.053_b0020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2188\/jea.JE20210513","article-title":"The Longevity Improvement & Fair Evidence (LIFE) study: Overview of the study design and baseline participant profile","volume":"33","author":"Fukuda","year":"2023","journal-title":"J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.11.053_b0025","unstructured":"LIFE study. 2023:https:\/\/life.hcam.med.kyushu-u.ac.jp\/. (in Japanese) [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.11.053_b0030","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2023.11.053_b0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5227","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2023.11.053_b0040","article-title":"Pneumococcal Conjugate Vaccine Safety in Elderly Adults. Open Forum","volume":"5","author":"Tseng","year":"2018","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2023.11.053_b0045","unstructured":"Ministry of health Labour and Welfare. The reporting criteria for adverse events following immunization in Japan. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou20\/hukuhannou_houkoku\/dl\/r01youshiki_01_02.pdf. (in Japanese) [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.11.053_b0050","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jclinepi.2005.11.012","article-title":"Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations","volume":"59","author":"Glanz","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.11.053_b0055","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.11.053_b0060","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.11.053_b0065","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.053_b0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.11.053_b0075","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2022.07.002","article-title":"Influenza vaccine effectiveness against hospitalization during the 2018\/2019 season among older persons aged >\/= 75 years in Japan: The LIFE-VENUS study","volume":"40","author":"Mimura","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.053_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijid.2022.10.001","article-title":"Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study","volume":"125","author":"Mimura","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.11.053_b0085","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.11.053_b0090","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1542\/peds.2007-1129","article-title":"A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children","volume":"121","author":"Glanz","year":"2008","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23013993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23013993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:32:09Z","timestamp":1759404729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23013993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23013993"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.11.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune thrombocytopenic purpura and Guillain-Barr\u00e9 syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.11.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}